Hormonal
PYY1-36 infusion does not significantly reduce energy intake in lean or obese subjects, although it may lower hunger ratings in lean individuals at low doses.
PYY1-36 infusions do not reduce food intake, even at higher doses. While it may slightly lower hunger feelings in lean people, it does not translate to eating less. It also increases heart rate and insulin response without the benefit of reduced calorie consumption, making it an ineffective strategy for weight management.
PYY1–36 had no effect on EI and no clear effects on appetite but resulted in increased heart rate and postprandial insulin response.
Why this rating
Randomized, blinded, crossover study with larger sample size for PYY1-36 (n=24) compared to high-dose PYY3-36.
Source
Effects of PYY<sub>1–36</sub>and PYY<sub>3–36</sub>on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects
Birgitte Sloth et al. · American Journal of Physiology-Endocrinology and Metabolism · 2006
DOI 10.1152/ajpendo.00450.2006
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →